Randomized trial · people
Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4
Checked against the paper Randomized trialPublished by PepVault
The takeaway
A daily 25 mg semaglutide pill led to clearly more weight loss than placebo over 64 weeks, with stomach and gut side effects in 74.0% of users.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2025
- Journal
- N Engl J Med
What they tested
Does a once-daily 25 mg semaglutide pill lead to more weight loss than a placebo in adults with overweight or obesity who do not have diabetes?
How the study was done
A double-blind, randomized, placebo-controlled trial lasting 71 weeks at 22 sites in four countries. Adults without diabetes with a BMI (body-mass index) of 30 or higher, or 27 or higher plus at least one weight-related health problem, were assigned 2:1 to the pill (205 people) or a placebo, a dummy pill (102 people), with lifestyle support in both groups.

Model. Individual results vary.
What they found
At week 64, body weight changed by an estimated -13.6% on oral semaglutide and -2.2% on placebo, a difference of -11.4 percentage points (95% confidence interval, -13.9 to -9.0). People on the pill were significantly more likely to lose at least 5%, 10%, 15% and 20% of their weight, and more often improved on a physical function score from a weight-related quality-of-life questionnaire (IWQOL-Lite-CT). Stomach and gut side effects were more common on the pill than on placebo (74.0% vs. 42.2%).
What it doesn’t show
The trial tested a single dose against placebo only, so it does not compare the pill with injectable semaglutide or other doses, and it excluded people with diabetes. It was funded by Novo Nordisk.
The paper
Wharton et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025.
The compounds
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.